|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
314.65
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 23.72 | 0.72 | 2.34 | 3.64 | 6.31 | CEPS(Rs) | 24.70 | 1.62 | 3.20 | 4.45 | 3.92 | DPS(Rs) | 1.50 | 0.50 | 0.00 | 0.00 | 1.00 | Book NAV/Share(Rs) | 90.01 | 66.62 | 65.04 | 62.11 | 117.59 | Tax Rate(%) | 4.13 | 38.37 | 21.82 | 20.41 | 10.57 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 1.04 | 3.52 | 15.34 | 14.18 | 11.75 | EBIT Margin(%) | 152.58 | 8.06 | 17.71 | 27.63 | 23.83 | Pre Tax Margin(%) | 149.09 | 8.04 | 17.69 | 27.57 | 23.69 | PAT Margin (%) | 142.93 | 4.95 | 13.83 | 21.94 | 21.18 | Cash Profit Margin (%) | 148.79 | 11.18 | 18.93 | 26.87 | 26.35 | Performance Ratios | | | | | | ROA(%) | 26.18 | 1.00 | 3.39 | 5.40 | 4.83 | ROE(%) | 30.29 | 1.09 | 3.68 | 6.01 | 5.51 | ROCE(%) | 29.84 | 1.74 | 4.65 | 7.46 | 6.06 | Asset Turnover(x) | 0.18 | 0.20 | 0.24 | 0.25 | 0.23 | Sales/Fixed Asset(x) | 0.88 | 0.84 | 1.05 | 0.90 | 0.76 | Working Capital/Sales(x) | 1.07 | 0.96 | 1.25 | 1.47 | 1.18 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 1.14 | 1.20 | 0.95 | 1.11 | 1.32 | Receivable days | 124.41 | 137.12 | 106.04 | 135.38 | 167.78 | Inventory Days | 100.88 | 102.10 | 86.88 | 122.68 | 139.36 | Payable days | 160.73 | 170.01 | 204.20 | 256.89 | 283.20 | Valuation Parameters | | | | | | PER(x) | 8.70 | 466.53 | 174.89 | 74.43 | 48.45 | PCE(x) | 8.35 | 206.72 | 127.75 | 60.77 | 77.90 | Price/Book(x) | 2.29 | 5.02 | 6.29 | 4.36 | 5.20 | Yield(%) | 0.73 | 0.15 | 0.00 | 0.00 | 0.16 | EV/Net Sales(x) | 12.72 | 22.75 | 23.89 | 16.14 | 20.37 | EV/Core EBITDA(x) | 85.97 | 159.29 | 104.72 | 65.82 | 113.96 | EV/EBIT(x) | 8.34 | 282.32 | 134.90 | 58.42 | 85.47 | EV/CE(x) | 2.08 | 4.84 | 6.13 | 4.26 | 5.06 | M Cap / Sales | 12.43 | 23.11 | 24.18 | 16.33 | 20.53 | Growth Ratio | | | | | | Net Sales Growth(%) | 14.65 | -14.31 | 2.01 | 11.35 | -26.19 | Core EBITDA Growth(%) | 18.77 | -46.34 | -5.13 | 52.79 | -27.93 | EBIT Growth(%) | 2,070.45 | -61.00 | -34.62 | 29.09 | 38.72 | PAT Growth(%) | 3,208.25 | -69.30 | -35.71 | 15.33 | 58.62 | EPS Growth(%) | 3,208.44 | -69.32 | -35.71 | -42.33 | 58.62 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.12 | 0.01 | 0.00 | 0.00 | 0.01 | Current Ratio(x) | 3.68 | 4.07 | 3.94 | 2.86 | 2.53 | Quick Ratio(x) | 2.87 | 3.15 | 3.19 | 2.17 | 1.79 | Interest Cover(x) | 43.69 | 350.25 | 898.00 | 457.83 | 163.69 | Total Debt/Mcap(x) | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
|
|
|
|
|
|